President and Chief Executive Officer
Dr. Seely is an endocrinologist with over 20 years of drug development experience and biopharmaceutical company leadership. At Medivation, she served as Chief Medical Officer from 2005-2015 and led the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer from IND-enabling studies through to NDA approval and post-approval clinical studies. Dr. Seely currently serves on the Board of Directors of Blueprint Medicines Corporation. She completed her residency in internal medicine at Yale-New Haven Hospital and a basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego.
Chief Financial Officer
Mr. Karbe previously served as Executive Vice President and Chief Financial Officer for Exelixis from 2004-2014. Earlier in his career, he worked as an investment banker for Goldman Sachs & Co., where he served most recently as Vice President in the healthcare group focusing on corporate finance and mergers and acquisitions in the biotechnology industry. He also previously served as President of The Color Run, a global mass participation events platform. He currently serves on the Board of Directors of Arbutus Biopharma Corporation and Kolltan Pharmaceuticals, Inc. He received his Diplom-Kaufmann from the WHU-Otto Beisheim Graduate School of Management, Koblenz, Germany.
Senior Vice President, Product Development
Mr. Selby has more than two decades of pharma and biotech industry experience. Previously, he worked at Medivation from 2007-2016, where he served most recently as Senior Vice President, Product Strategy. There he provided oversight for the development programs for investigational oncology products talazoparib and pidilizumab and oversaw the acquisition of products, technologies and companies for Medivation’s clinical pipeline. He also played a key leadership role in the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer. Earlier in his career, he held roles at Alza/J&J, Nuvelo, Corgentech and Gilead Sciences. He received his M.S. in statistics from Kansas State University and his B.A. in mathematics from Washburn University.
Vice President, Clinical Development
Dr. Williams previously served as the R&D Group Project Leader in Women’s Health at AbbVie. During her 18-year career at Abbott/AbbVie, she held multiple roles of increasing responsibility across R&D, spanning all phases of drug development and multiple therapeutic areas, including women’s health. Earlier in her career, she worked for Pharmacia and Upjohn. She received her B.S. in biochemistry from Mississippi State University and her M.D. from the University of Iowa. She completed her internal medicine training at the University of Michigan, where she served as chief resident and faculty. She completed subspecialty training in infectious diseases at the University of Washington, where she also obtained an M.P.H. in epidemiology.
Executive Director, Human Resources
Ms. Tran has approximately 20 years of HR experience at both large global enterprises and small emerging companies and has worked with business leaders, managers and HR partners on the execution of a broad range of HR projects. Previously, she held roles at Raptor Pharmaceuticals, Johnson & Johnson, Medivation and Ipsen. She received her M.B.A and M.S. in human resources management from Golden Gate University and a B.A. in communication studies from San Jose State University.